These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 30554795)
41. Potential economic benefits of eliminating canine rabies. Shwiff S; Hampson K; Anderson A Antiviral Res; 2013 May; 98(2):352-6. PubMed ID: 23499650 [TBL] [Abstract][Full Text] [Related]
42. Estimating the economic impact of canine rabies to Viet Nam 2005-2014. Shwiff SA; Brown VR; Dao TT; Elser J; Trung HX; Tien NN; Huong NT; Huong NTT; Riewpaiboon A; Ernst K; Shwiff S; Payne D PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006866. PubMed ID: 30307947 [TBL] [Abstract][Full Text] [Related]
43. How geographic access to care shapes disease burden: The current impact of post-exposure prophylaxis and potential for expanded access to prevent human rabies deaths in Madagascar. Rajeev M; Guis H; Edosoa GT; Hanitriniaina C; Randrianarijaona A; Mangahasimbola RT; Hierink F; Ramiandrasoa R; Nely J; Heraud JM; Andriamandimby SF; Baril L; Metcalf CJE; Hampson K PLoS Negl Trop Dis; 2021 Apr; 15(4):e0008821. PubMed ID: 33901194 [TBL] [Abstract][Full Text] [Related]
44. Towards Canine Rabies Elimination in KwaZulu-Natal, South Africa: Assessment of Health Economic Data. Shwiff SA; Hatch B; Anderson A; Nel LH; Leroux K; Stewart D; de Scally M; Govender P; Rupprecht CE Transbound Emerg Dis; 2016 Aug; 63(4):408-15. PubMed ID: 25414096 [TBL] [Abstract][Full Text] [Related]
45. Towards canine rabies elimination: Economic comparisons of three project sites. Elser JL; Hatch BG; Taylor LH; Nel LH; Shwiff SA Transbound Emerg Dis; 2018 Feb; 65(1):135-145. PubMed ID: 28299897 [TBL] [Abstract][Full Text] [Related]
46. Postexposure prophylaxis for rabies in resource-limited/poor countries. Shantavasinkul P; Wilde H Adv Virus Res; 2011; 79():291-307. PubMed ID: 21601051 [TBL] [Abstract][Full Text] [Related]
47. The Cost of Canine Rabies on Four Continents. Anderson A; Shwiff SA Transbound Emerg Dis; 2015 Aug; 62(4):446-52. PubMed ID: 24112194 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. Hampson K; Cleaveland S; Briggs D PLoS Negl Trop Dis; 2011 Mar; 5(3):e982. PubMed ID: 21408121 [TBL] [Abstract][Full Text] [Related]
49. Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review. Davlin SL; Vonville HM Vaccine; 2012 May; 30(24):3492-502. PubMed ID: 22480924 [TBL] [Abstract][Full Text] [Related]
50. Mass vaccination of dogs, control of canine populations and post-exposure vaccination--necessary but not sufficient for achieving childhood rabies elimination. Durrheim DN; Rees H; Briggs DJ; Blumberg LH Trop Med Int Health; 2015 Jun; 20(6):682-4. PubMed ID: 25682707 [No Abstract] [Full Text] [Related]
51. Rabies: changing prophylaxis and new insights in pathophysiology. Ugolini G; Hemachudha T Curr Opin Infect Dis; 2018 Feb; 31(1):93-101. PubMed ID: 29293476 [TBL] [Abstract][Full Text] [Related]
52. Economic evaluation of an oral rabies vaccination program for control of a domestic dog-coyote rabies epizootic: 1995-2006. Shwiff SA; Kirkpatrick KN; Sterner RT J Am Vet Med Assoc; 2008 Dec; 233(11):1736-41. PubMed ID: 19046031 [TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis. Tantawichien T; Sibunruang S; Tantawichien T; Angsanakul J; Benjavongkulchai M; Limsuwan K; Udomchaisakul P; Khomvilai S; Sitprija V Expert Rev Vaccines; 2014 Dec; 13(12):1593-601. PubMed ID: 25315021 [TBL] [Abstract][Full Text] [Related]
54. Healthcare utilization, provisioning of post-exposure prophylaxis, and estimation of human rabies burden in Madagascar. Rajeev M; Edosoa G; Hanitriniaina C; Andriamandimby SF; Guis H; Ramiandrasoa R; Ratovoson R; Randrianasolo L; Andriamananjara M; Heraud JM; Baril L; Metcalf CJE; Hampson K Vaccine; 2019 Oct; 37 Suppl 1(Suppl 1):A35-A44. PubMed ID: 30509692 [TBL] [Abstract][Full Text] [Related]
55. [Cost-effectiveness analysis of rabies immunization strategy based on dynamic-decision tree model]. Wang DL; Zhang XF; Wang XC; Wang YT; Zhang R; Chen YY; Wang Q; Yue N; Bao CC; Zhou MH; Jin H Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Aug; 53(8):804-810. PubMed ID: 31378040 [No Abstract] [Full Text] [Related]
56. New human rabies vaccines in the pipeline. Fooks AR; Banyard AC; Ertl HCJ Vaccine; 2019 Oct; 37 Suppl 1(Suppl 1):A140-A145. PubMed ID: 30153997 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of post-exposure prophylaxis practices to improve the cost-effectiveness of rabies control in human cases potentially exposed to rabies in southern Bhutan. Penjor K; Marquetoux N; Dorji C; Penjor K; Dorjee S; Dorjee C; Jolly PD; Morris RS; McKenzie JS BMC Infect Dis; 2020 Mar; 20(1):203. PubMed ID: 32143641 [TBL] [Abstract][Full Text] [Related]
58. A review of the economics of the prevention and control of rabies. Part 2: Rabies in dogs, livestock and wildlife. Meltzer MI; Rupprecht CE Pharmacoeconomics; 1998 Nov; 14(5):481-98. PubMed ID: 10344914 [TBL] [Abstract][Full Text] [Related]
59. Control of canine rabies in developing countries: key features and animal welfare implications. Aréchiga Ceballos N; Karunaratna D; Aguilar Setién A Rev Sci Tech; 2014 Apr; 33(1):311-21. PubMed ID: 25000804 [TBL] [Abstract][Full Text] [Related]
60. Review on dog rabies vaccination coverage in Africa: a question of dog accessibility or cost recovery? Jibat T; Hogeveen H; Mourits MC PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003447. PubMed ID: 25646774 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]